Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo aims to tackle tough bone cancer

NCT ID NCT07144254

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called tegavivint combined with the chemotherapy gemcitabine in 24 people whose osteosarcoma (a type of bone cancer) has returned or not responded to prior treatment. The main goal is to find the safest dose of tegavivint when given with gemcitabine, and to see if the combination can control the disease. Participants receive the drugs intravenously over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tegavivint and gemcitabine
What this could lead to
If successful, this could lead to a new treatment option for patients with osteosarcoma that has come back or not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, focused on finding a safe dose. It is not yet known if the combination will effectively control the cancer, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma pediatric osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA IN CHILDREN OSTEOSARCOMA RECURRENT REFRACTORY OSTEOSARCOMA RELAPSED OSTEOSARCOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Arthur M. Blank Children's Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.